Form 4: Arcadia Biosciences CFO Mark Kawakami Reports Stock Option Grant

Chief Financial Officer of Arcadia Biosciences, Mark Kawakami, reports the acquisition of stock options.

Summary

• Mark Kawakami, the Chief Financial Officer of Arcadia Biosciences, filed a Form 4 on May 12, 2025, reporting changes in beneficial ownership.
• The report details the acquisition of stock options granting the right to buy 12,500 shares of common stock at an exercise price of $3.88.
• These options were granted on May 9, 2025, and vest over four years: 25% vests on the first anniversary, and the remaining 75% vests in 36 equal monthly installments.
• Following the reported transaction, Kawakami directly owns 33,987 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The stock option grant aligns the CFO's interests with shareholders, potentially benefiting them through increased company value.

Key Dates

Keywords

Form 4, stock options, beneficial ownership, Arcadia Biosciences, RKDA, Kawakami, CFO